Clinical Trial Update: Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 [Phase 3]

View source ↗

Summary

Phase 3 safety and efficacy trial comparing pegylated interferon lambda with and without daclatasvir against pegylated interferon alfa plus ribavirin in hepatit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Daclatasvir (daclatasvir)
• Pegylated Interferon Lambda (pegylated interferon lambda-1a)
• Pegylated interferon alfa (pegylated interferon alfa)
• Ribavirin (ribavirin)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C Virus (HCV) | Phase 3 | Status: COMPLETED